Modality
Degrader
MOA
CD3xCD20
Target
KRASG12D
Pathway
Complement
Myelofibrosis
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
Jun 2018
→ Sep 2027
Phase 1Current
NCT05423596
318 pts·Myelofibrosis
2019-08→TBD·Active
NCT06105113
2,525 pts·Myelofibrosis
2018-06→2027-09·Terminated
2,843 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-221.5y awayPh2 Data· Myelofibrosis
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Termina…
P1/2
Active
Catalysts
Ph2 Data
2027-09-22 · 1.5y away
Myelofibrosis
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05423596 | Phase 1/2 | Myelofibrosis | Active | 318 | Mayo |
| NCT06105113 | Phase 1/2 | Myelofibrosis | Terminated | 2525 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D |